UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

Translational psychiatry, 2012-03, Vol.2 (3), p.e94-e94

2012

Volltextzugriff (PDF)

High Throughput Lipidomic Profiling of Schizophrenia and Bipolar Disorder Brain Tissue Reveals Alterations of Free Fatty Acids, Phosphatidylcholines, and Ceramides

Journal of proteome research, 2008-10, Vol.7 (10), p.4266-4277

2008

Volltextzugriff (PDF)

Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence

Frontiers in pharmacology, 2016-11, Vol.7, p.422-422

2016

Volltextzugriff (PDF)

Global proteomic profiling reveals altered proteomic signature in schizophrenia serum

Molecular psychiatry, 2010-11, Vol.15 (11), p.1088-1100

2010

Volltextzugriff (PDF)

Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients

Molecular psychiatry, 2011-08, Vol.16 (8), p.848-859

2011

Volltextzugriff (PDF)

Differential melatonin alterations in cerebrospinal fluid and serum of patients with major depressive disorder and bipolar disorder

Comprehensive psychiatry, 2016-07, Vol.68, p.34-39

2016

Volltextzugriff (PDF)

Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset

Translational psychiatry, 2015-07, Vol.5 (7), p.e601-e601

2015

Volltextzugriff (PDF)

Marked reduction of soluble superoxide dismutase-1 (SOD 1) in cerebrospinal fluid of patients with recent-onset schizophrenia

Molecular psychiatry, 2013-01, Vol.18 (1), p.10-11

2013

Volltextzugriff (PDF)

Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients

Molecular psychiatry, 2010-02, Vol.15 (2), p.118-119

2010

Volltextzugriff (PDF)

Elevated endogenous cannabinoids in schizophrenia

Neuroreport, 1999-06, Vol.10 (8), p.1665-1669

1999

Volltextzugriff (PDF)

Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues

Molecular psychiatry, 2008-12, Vol.13 (12), p.1118-1128

2008

Volltextzugriff (PDF)

Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression

Journal of Neural Transmission, 2007-08, Vol.114 (8), p.1055-1063

2007

Volltextzugriff (PDF)

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

Translational psychiatry, 2012-03, Vol.2 (3), p.e94

2012

Volltextzugriff (PDF)

Repurposed drugs for the treatment of schizophrenia and bipolar disorders

Current topics in medicinal chemistry, 2013-09, Vol.13 (18), p.2364-2385

2013

Volltextzugriff (PDF)

Complement proteins are elevated in blood serum but not CSF in clinical high-risk and antipsychotic-naïve first-episode psychosis

Brain, behavior, and immunity, 2023-10, Vol.113, p.136-144

2023

Volltextzugriff (PDF)

Identification of a biological signature for schizophrenia in serum

Molecular psychiatry, 2012-05, Vol.17 (5), p.494-502

2012

Volltextzugriff (PDF)

Serum proteomic profiling of major depressive disorder

Translational psychiatry, 2015-07, Vol.5 (7), p.e599-e599

2015

Volltextzugriff (PDF)

The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics

Schizophrenia bulletin, 2015-05, Vol.41 (3), p.549-558

2015

Volltextzugriff (PDF)

Reduced binocular depth inversion in schizophrenic patients

Schizophrenia research, 2002, Vol.53 (1), p.101-108

2002

Volltextzugriff (PDF)

Pathogen-mediated NMDA receptor autoimmunity and cellular barrier dysfunction in schizophrenia

Translational psychiatry, 2017-08, Vol.7 (8), p.e1186-e1186

2017

Volltextzugriff (PDF)

Treatment of Alcohol Withdrawal Syndrome with Gabapentin

Pharmacopsychiatry, 1999-05, Vol.32 (3), p.107-109

1999

Volltextzugriff (PDF)

Improvement of general symptoms in a chronic psychotic patient treated with finasteride: case report

Pharmacopsychiatry, 2008-05, Vol.41 (3), p.115-116

2008

Volltextzugriff (PDF)

Differential effects on T-cell function following exposure to serum from schizophrenia smokers

Molecular psychiatry, 2010-04, Vol.15 (4), p.364-371

2010

Volltextzugriff (PDF)

Systems-theory of Psychosis - the Relevance of ”Internal Censorship

Pharmacopsychiatry, 2006-02, Vol.39 (S 1), p.52-53

2006

Volltextzugriff (PDF)

Towards a Cannabinoid Hypothesis of Schizophrenia: Cognitive Impairments Due to Dysregulation of the Endogenous Cannabinoid System

Pharmacology, biochemistry and behavior, 1997-04, Vol.56 (4), p.803-807

1997

Volltextzugriff (PDF)

1 – 25 von 158

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(152)
Mit Volltextzugriff
(136)

Publikationsform

Sprache

Englisch
(136)
Deutsch
(23)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

High Throughput Lipidomic Profiling of Schizophrenia and Bipolar Disorder Brain Tissue Reveals Alterations of Free Fatty Acids, Phosphatidylcholines, and Ceramides

Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence

Global proteomic profiling reveals altered proteomic signature in schizophrenia serum

Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients

Differential melatonin alterations in cerebrospinal fluid and serum of patients with major depressive disorder and bipolar disorder

Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset

Marked reduction of soluble superoxide dismutase-1 (SOD 1) in cerebrospinal fluid of patients with recent-onset schizophrenia

Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients

Elevated endogenous cannabinoids in schizophrenia

Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues

Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

Repurposed drugs for the treatment of schizophrenia and bipolar disorders

Complement proteins are elevated in blood serum but not CSF in clinical high-risk and antipsychotic-naïve first-episode psychosis

Identification of a biological signature for schizophrenia in serum

Serum proteomic profiling of major depressive disorder

The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics

Reduced binocular depth inversion in schizophrenic patients

Pathogen-mediated NMDA receptor autoimmunity and cellular barrier dysfunction in schizophrenia

Treatment of Alcohol Withdrawal Syndrome with Gabapentin

Improvement of general symptoms in a chronic psychotic patient treated with finasteride: case report

Differential effects on T-cell function following exposure to serum from schizophrenia smokers

Systems-theory of Psychosis - the Relevance of ”Internal Censorship

Towards a Cannabinoid Hypothesis of Schizophrenia: Cognitive Impairments Due to Dysregulation of the Endogenous Cannabinoid System

Suchergebnisse filtern